GRPR and prostate cancer: For example, in case of the former approach, the 64Cu/67Cu pair could be utilized, where [64Cu]Cu-SAR-BBN is used for PET imaging and [67Cu]Cu-SAR-BBN for β− therapy of prostate cancer (A phase I/IIa theranostic study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPR-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617 2022; Szymański et al. 2012; Krasnovskaya et al. 2023; Kelly et al. 2020).